trending Market Intelligence /marketintelligence/en/news-insights/trending/7ktSoCNjqACKerQyCYiweg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Cancer Genetics closes common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Cancer Genetics closes common stock offering

Cancer Genetics Inc. closed an underwritten public offering of 13,333,334 common shares at 22.5 cents each.

The company raised gross proceeds of $3 million.

Net proceeds will be used to pay costs related to potential forbearance agreements Cancer Genetics is negotiating with its banks, as well as costs related to on-going strategic initiatives. Remaining funds, if any, will go toward working capital and other general corporate purposes.

Underwriters were granted a 45-day option to buy 2 million additional shares, also at 22.5 cents each.

H.C. Wainwright & Co. acted as the sole book-running manager for the offering.

Rutherford, N.J.-based Cancer Genetics develops, commercializes and provides molecular and biomarker-based tests and services.